MEF2 is upregulated during cardiac hypertrophy and is required for normal post-natal growth of the myocardium

Current Biology

Volumn 9, Issue 20, 1999, Pages 1203-1206

  Kolodziejczyk, Steven M ^a   Wang, Ling ^a   Balazsi, Kim ^a   Derepentigny, Yves ^a   Kothary, Rashmi ^a   Megeney, Lynn A ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA; MAMMALIA; MUS MUSCULUS;

EID: 0033592696     PISSN: 09609822     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9822(00)80027-5     Document Type: Article

References (30)

1. Nag AC, Carey TR, Cheng M: Assessment of cardiomyocyte DNA synthesis in rat heart cells after injury and the regeneration of myocardia. Tissue Cell 1983, 15:597-613.
2. Soonpa MH, Field LJ: Assessment of cardiomyocyte DNA synthesis in normal and injured adult mouse hearts. Am J Physiol 1997, 272:H220-H226.
3. Claycomb WC: Control of cardiac muscle cell division. Trends Cardiovasc Med 1992, 2:231-236.
4. Kim HD, Kim DJ, Lee IJ, Rah BJ, Sawa Y, Schaper J: Human fetal heart development after mid-term: morphometry and ultrastructural study. J Mol Cell Cardiol 1992, 24:949-965.
5. Li F, Wang X, Capasso JM, Gerdes AM: Rapid transition of cardiac myocytes from hyperplasia to hypertrophy during postnatal development. J Mol Cell Cardiol 1996, 28:1737-1746.
6. Schwartz K, Boheler KR, de la Bastie D, Lompre AM, Mercadier JJ: Switches in cardiac muscle gene expression as a result of pressure and volume overload. Am J Physiol 1992, 262:R364-R369.
7. Katz AM: The cardiomyopathy of overload: an unnatural growth response. Eur Heart J 1995, 16 Suppl. O:110-114.
8. Vikstrom KL, Leinwand LA: Contractile protein mutations and heart disease. Curr Opin Cell Biol 1996, 8:97-105.
9. Bonne G, Carrier L, Richard P, Hainque B, Schwartz K: Familial hypertrophy cardiomyopathy: from mutations to functional defects. Circ Res 1998, 83:580-593.
10. Hudlicka O, Brown MD: Postnatal growth of the heart and its blood vessels. J Vasc Res 1996, 33:266-287.
11. Chien KR, Zhu H, Knowlton KU, Miller-Hance W, van Bilsen M, Obrien TX, Evans SM: Transcriptional regulation during cardiac growth and development. Annu Rev Physiol 1993, 55:77-95.
12. Sadoshima J, Izumo S: The cellular and molecular response of cardiac myocytes to mechanical stress. Annu Rev Physiol 1997, 59:551-571.
13. Molkentin JD, Lu J-R, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN: A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998, 93:215-228.
14. Sussman MA, Lim HW, Gude N, Taigen T, Olson EN, Robbins J, et al.: Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science 1998, 281:1690-1693.
15. Luo Z, Shyu KG, Gualberto A, Walsh K: Calcineurin inhibitors and cardiac hypertrophy. Nat Med 1998, 4:1092-1093.
16. Mende U, Kagen A, Cohen A, Aramburu J, Schoen FJ, Neer EJ: Transient cardiac expression of constitutively active Gaq leads to hypertrophy and dilated cardiomyopathy by calcineurin-dependent and independent pathways. Proc Natl Acad Sci USA 1998, 95:13893-13898.
17. Megeney LA, Kablar B, Perry RLS, Ying C, May L, Rudnicki MA: Severe cardiomyopathy in mice lacking dystrophin and MyoD. Proc Natl Acad Sci USA 1999, 96:220-225.
18. Zechner D, Thueraf DJ, Hanford DS, McDonough PM, Glembotski CC: A role for the p38 mitogen-activated protein kinase pathway in myocardial cell growth, sarcomeric organization, and cardiac-specific gene expression. J Cell Biol 1997, 139:115-127.
19. Nemoto S, Sheng Z, Lin A: Opposing effects of Jun kinase and p38 mitogen-activated protein kinases on cardiomyocyte hypertrophy. Mol Cell Biol 1998, 18:3518-3526.
20. Molkentin JD, Markham BE: Myocyte-specific enhancer-binding factor (MEF-2) regulates alpha-cardiac myosin heavy chain gene expression in vitro and in vivo. J Biol Chem 1993, 268:19512-19520.
21. Black BL, Olson EN: Transcriptional control of muscle development by myocyte enhancer factor-2 (MEF2) proteins. Annu Rev Cell Dev Biol 1998, 14:167-196.
22. Jones WK, Sanchez A, Robbins J: Murine pulmonary myocardium: developmental analysis of cardiac gene expression. Dev Dyn 1994, 200:117-128.
23. Han J, Jiang Y, Li Z, Kravcenko VV, Ulevitch, RJ: Activation of the transcription factor MEF2C by the MAP kinase p38 in inflammation. Nature 1997, 386:296-299.
24. Zhao M, New L, Kravcehnko VV, Kato Y, Gram H, di Padova F, et al.: Regulation of the MEF2 family of transcription factors by p38. Mol Cell Biol 1999, 19:21-30.
25. Ornatsky OI, Andreucci JJ, McDermott JC: A dominant-negative form of transcription factor MEF2 inhibits myogenesis. J Biol Chem 1997, 272:33271-33278.
26. Ornatsky OI, Cox DM, Tangirala P, Andreucci JJ, Quinn ZA, Wrana JL, et al.: Post-translational control of the MEF2A transcriptional regulatory protein. Nucleic Acids Res 1999, 27:2646-2654.
27. Olson EN, Srivastava D: Molecular pathways controlling heart development. Science 1996, 272:671-676.
28. Bancroft JD, Stevens A: Theory and Practice of Histological Techniques. Edinburgh: Churchill Livingston; 1990.
29. Jones WK, Grupp IL, Doetschman T, Grupp G, Osinska H, Hewett TE, et al.: Ablation of the murine α-myosin heavy chain gene leads to dosage effects and functional deficits in the heart. J Clin Invest 1996, 98:1906-1917.
30. Guy L-G, Kothary R, DeRepentigny Y, Delvoye N, Ellis J, Wall L: The β-globin locus control region enhances transcription of but does not confer position-independent expression onto the lacZ gene in transgenic mice. EMBO J 1996, 15:3713-3721.